Related Experiment Video
Updated: Jul 2, 2026
08:54
Validated LC-MS/MS Panel for Quantifying 11 Drug-Resistant TB Medications in Small Hair Samples
Published on: May 19, 2020
Pyrazinamide serum levels in childhood tuberculosis
1Department of Paediatric Pneumology and Immunology, Helios Klinikum Emil von Behring, Chest Hospital Heckeshorn, Berlin, Germany.
Summary
Pyrazinamide (PZA) serum levels in children aged 1-14 years were assessed. A dosage of 30 mg/kg PZA achieved effective serum concentrations, regardless of age or combination therapy, supporting its use in pediatric tuberculosis treatment.
Area of Science:
- Pharmacology
- Pediatrics
- Infectious Diseases
Background:
- Pyrazinamide (PZA) is a crucial first-line medication for tuberculosis (TB) treatment.
- Understanding PZA pharmacokinetics in children is vital for optimizing TB therapy.
Purpose of the Study:
- To determine pyrazinamide serum levels in pediatric patients.
- To evaluate the influence of age and combination therapy on PZA serum concentrations.
- To establish an appropriate PZA dosage for children.
Main Methods:
- Serum levels of PZA were measured in 34 children (aged 1-14 years).
- Patients received either PZA monotherapy or combination therapy with isoniazid and rifampicin.
- PZA dosage was administered at 30 mg/kg.
Main Results:
- Serum PZA levels did not show statistically significant differences based on age.
- Monotherapy and combination therapy did not significantly impact PZA serum levels.
- A PZA dosage of 30 mg/kg achieved efficient serum concentrations in children.
Conclusions:
- A PZA dosage of 30 mg/kg is appropriate and effective for children aged 1-14 years.
- PZA dosage should be based on body weight due to uniform body distribution.
- This dosage ensures therapeutic PZA serum levels in pediatric TB patients.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Pulmonary Tuberculosis IV
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:31Pulmonary Tuberculosis III
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
01:28Pulmonary Tuberculosis II
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...